SHANGHAI, CHINA – [Date of publication, e.g., August 28, 2026] – AusperBio Therapeutics and its affiliate Ausper Biopharma have announced the successful closure of a $120 million Series C funding round, propelling the company’s pioneering efforts to develop novel therapies for chronic hepatitis B (CHB). This significant capital injection brings AusperBio’s total funding raised since 2024 to an impressive $360 million, underscoring strong investor confidence in its innovative oligonucleotide platforms and its ambitious pursuit of a functional cure for one of the world’s most persistent global health challenges.
n
The Series C round was spearheaded by a prominent, yet undisclosed, strategic investor, signaling a deep institutional belief in AusperBio’s scientific vision and commercial potential. New investor RA Capital Management, a leading healthcare and life sciences investment firm, also participated, joining a robust syndicate of existing investors including HanKang Capital, Qiming Venture Partners, and CDH Investments. This diverse group of financial and strategic partners highlights the broad appeal of AusperBio’s approach and the perceived high-growth trajectory of its pipeline assets.
n
The substantial new funds are earmarked primarily for the accelerated advancement of AHB-137, AusperBio’s lead antisense oligonucleotide (ASO) therapy for CHB. This includes progressing its critical Phase III registrational program, particularly in China, and initiating comprehensive preparations for its eventual commercial launch. Beyond AHB-137, the capital will also fuel the development of AHB-171, a cutting-edge hepatocyte-targeted small interfering ribonucleic acid (siRNA) therapeutic candidate. Crucially, a portion of the investment will be dedicated to exploring and developing next-generation combination treatment approaches, which AusperBio believes are key to achieving a definitive functional cure for CHB, rather than just managing the disease.
n
Dr. Guofeng Cheng, co-founder and CEO of AusperBio, articulated the profound significance of this financing, stating, "This financing represents an important inflection point for AusperBio as we advance AHB-137 toward potential commercialisation while developing next-generation therapies for CHB. We are grateful for the continued confidence of our existing investors and pleased to welcome RA Capital to AusperBio. We look forward to building on this momentum to advance our strategy toward functional cure and unlock new opportunities across our oligonucleotide platforms." His remarks underscore the dual focus of the company: bringing its most advanced candidate to market while simultaneously innovating for future, more comprehensive solutions.
n
Main Facts: A Landmark Investment in Hepatitis B Innovation
n
AusperBio’s latest $120 million Series C funding round represents a pivotal moment for the biotech firm and the broader fight against chronic hepatitis B. This injection of capital, which elevates the company’s total raised to $360 million since the beginning of 2024, firmly positions AusperBio as a leading contender in the race to deliver transformative therapies for CHB. The strategic leadership of an undisclosed investor, complemented by the entry of a respected healthcare investor like RA Capital Management, speaks volumes about the perceived value and potential of AusperBio’s scientific endeavors.
n
At the heart of AusperBio’s strategy is AHB-137, an antisense oligonucleotide therapy currently undergoing a Phase III registrational program in China. The funding will expedite its journey toward commercial readiness, a critical step in making this potentially life-changing treatment available to patients. Concurrently, the company is bolstering the development of AHB-171, a novel siRNA therapeutic that leverages AusperBio’s proprietary Au-HALO liver-targeting delivery platform. Both assets represent distinct yet complementary approaches to tackling the complex pathology of CHB.
n
The ultimate goal driving these investments is the pursuit of a "functional cure" for CHB. Unlike current treatments that primarily suppress the virus and often require lifelong adherence, a functional cure would mean sustained loss of hepatitis B surface antigen (HBsAg) and undetectable hepatitis B virus (HBV) DNA after discontinuing therapy, significantly improving patients’ quality of life and reducing long-term health risks. This ambitious objective, coupled with AusperBio’s innovative oligonucleotide platform, underscores why investors are committing substantial resources to the company. The funding ensures that AusperBio can not only push its lead candidates through late-stage clinical trials but also explore synergistic combination therapies that could unlock new frontiers in CHB treatment.
n
Chronology: AusperBio’s Rapid Ascent and Strategic Milestones
n
AusperBio’s journey to becoming a significant player in the biopharmaceutical landscape, particularly in the CHB therapeutic space, has been marked by rapid progress and strategic milestones, culminating in its impressive fundraising achievements. The company’s ability to secure $360 million in total capital since 2024 is a testament to its compelling scientific platform, the pressing unmet medical need it addresses, and the confidence garnered from its early clinical successes.
n
The development trajectory of AHB-137, AusperBio’s flagship antisense oligonucleotide therapy, has been a central narrative in the company’s growth. The drug has successfully navigated global Phase I and multiple Phase II studies, demonstrating encouraging safety and efficacy profiles that paved the way for its current Phase III registrational program in China. This progression through rigorous clinical stages highlights a systematic and evidence-based approach to drug development.
n
A crucial accelerant in AHB-137’s journey was the breakthrough therapy designation it received in China in July 2024. This prestigious designation, awarded by the National Medical Products Administration (NMPA), signifies that AHB-137 addresses a serious or life-threatening condition and has demonstrated preliminary clinical evidence of substantial improvement over existing therapies. Such a designation not only expedites regulatory review but also underscores the potential of AHB-137 to significantly alter the treatment paradigm for CHB patients in China, a country with one of the highest burdens of the disease globally.
n
The strategic decision to simultaneously advance AHB-171, a hepatocyte-targeted siRNA therapeutic candidate, reflects AusperBio’s commitment to a multi-pronged attack on CHB. The introduction of AHB-171, utilizing the company’s proprietary Au-HALO liver-targeting delivery platform, demonstrates an evolution in their therapeutic strategy, embracing different oligonucleotide modalities to maximize the chances of achieving a functional cure. This parallel development showcases AusperBio’s depth of scientific innovation and its long-term vision beyond a single drug candidate.
n
The consistent ability to attract and retain high-caliber investors, from early-stage venture capital firms like Qiming Venture Partners and CDH Investments to the recent participation of RA Capital Management and a strategic industry player, illustrates a sustained validation of AusperBio’s scientific roadmap and commercial strategy. Each funding round has built upon previous successes, providing the necessary capital to transition from preclinical research to late-stage clinical development and now, toward commercialization planning, all within a relatively condensed timeframe since 2024. This chronological progression of funding and clinical milestones paints a picture of a company executing effectively on its ambitious goals in a highly competitive biopharmaceutical landscape.
n
Supporting Data: The Global Burden, Therapeutic Innovation, and Market Confidence
n
The significant investment in AusperBio is underpinned by compelling data related to the global burden of chronic hepatitis B, the limitations of current treatments, the promise of oligonucleotide therapeutics, and the broader dynamics of biotech investment.
n
The Global Burden of Chronic Hepatitis B
n
Chronic hepatitis B remains a formidable global health crisis, affecting an estimated 296 million people worldwide. The World Health Organization (WHO) reports that CHB leads to approximately 820,000 deaths annually, primarily from cirrhosis and hepatocellular carcinoma (HCC), a deadly form of liver cancer. This makes CHB a leading cause of liver disease mortality globally. The majority of people living with CHB reside in the Western Pacific Region and the African Region, where prevalence can exceed 5-10% in some populations.
n
Current standard-of-care treatments, primarily nucleos(t)ide analogues (NAs), are effective at suppressing viral replication and reducing disease progression. However, they rarely lead to a "functional cure," defined as sustained HBsAg loss and seroconversion to anti-HBs antibodies, often requiring lifelong therapy. This lifelong treatment imposes a significant burden on patients, including daily medication adherence, potential side effects, and considerable healthcare costs. Moreover, even with viral suppression, a residual risk of liver complications persists. This substantial unmet medical need for a finite, curative treatment option creates an enormous market opportunity for innovative therapies.
n
AusperBio’s Therapeutic Approach: Targeting the Core of CHB
n
AusperBio’s pipeline is strategically designed to address the fundamental challenges of CHB.
n
AHB-137: An Antisense Oligonucleotide (ASO) for HBsAg SuppressionnAHB-137 represents a direct assault on the virus’s ability to produce hepatitis B surface antigen (HBsAg), a key viral protein that not only serves as a marker of infection but also plays a crucial role in immune evasion. By suppressing HBsAg production, AHB-137 aims to:
n
- n
- Inhibit viral deoxyribonucleic acid (DNA) replication: Reducing the viral load by preventing the virus from multiplying.
- Promote immune reactivation: Lowering HBsAg levels is believed to allow the host immune system to "see" the virus more effectively and mount a stronger, more sustained antiviral response. This immune reawakening is critical for achieving a functional cure.nThe progression of AHB-137 through global Phase I and multiple Phase II studies, demonstrating a favorable safety profile and significant HBsAg reduction, has built a strong foundation for its current Phase III registrational program in China. The breakthrough therapy designation further validates its potential to be a game-changer.
n
n
n
AHB-171: A Hepatocyte-Targeted Small Interfering Ribonucleic Acid (siRNA) with Au-HALO PlatformnAHB-171 introduces another powerful mechanism: small interfering RNA (siRNA). siRNAs work by harnessing the body’s natural RNA interference pathway to selectively degrade messenger RNA (mRNA) transcripts responsible for producing viral proteins. AHB-171 is designed to specifically target and suppress viral gene expression, leading to a profound reduction in all HBV antigens and viral components.
A critical innovation enabling AHB-171 is AusperBio’s proprietary Au-HALO liver-targeting delivery platform. Oligonucleotide therapeutics, while highly specific, face a major challenge: efficient and safe delivery to the target cells. The liver is the primary site of HBV replication, and the Au-HALO platform is engineered to ensure that AHB-171 is effectively and selectively delivered to hepatocytes (liver cells), maximizing its therapeutic impact while minimizing off-target effects. This targeted delivery is crucial for unlocking the full potential of siRNA technology in CHB.
The combination of these two distinct oligonucleotide modalities (ASO and siRNA) provides AusperBio with a robust strategy for achieving a functional cure. By attacking the virus through multiple pathways – directly inhibiting viral protein synthesis and promoting immune recovery – AusperBio aims to offer a comprehensive solution that goes beyond mere viral suppression.
The Oligonucleotide Therapy Landscape
Oligonucleotide therapeutics, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), represent a rapidly expanding and highly promising class of drugs. These nucleic acid-based medicines offer exquisite specificity, as they are designed to bind to specific RNA sequences, allowing for precise modulation of gene expression. This precision reduces the likelihood of off-target effects compared to traditional small molecule drugs.
Over the past decade, significant advancements in oligonucleotide chemistry, stability, and delivery technologies have led to the approval of several oligonucleotide drugs for various genetic and infectious diseases, demonstrating their clinical utility. Companies like Alnylam, Ionis, and Sarepta have paved the way, showcasing the therapeutic potential of this modality. AusperBio’s focus on CHB, a disease with a well-defined viral target and a critical need for new mechanisms, positions it at the forefront of applying these advanced technologies to a widespread infectious disease. The success of oligonucleotide therapies in rare diseases is now being extended to larger patient populations, and AusperBio is a key player in this expansion.
Investor Confidence and Market Dynamics
The participation of a strategic investor and a specialist healthcare fund like RA Capital Management, alongside continued support from existing investors, reflects several key factors:
- Strong Clinical Data: Positive results from Phase I and II trials for AHB-137 are critical de-risking factors.
- Large Unmet Need: The immense global burden of CHB and the limitations of current treatments present a substantial market opportunity for a functional cure.
- Validated Technology: The growing success of oligonucleotide therapies provides a robust scientific foundation.
- Proprietary Delivery Platform: The Au-HALO platform offers a competitive advantage in targeted delivery, a persistent challenge for oligonucleotide drugs.
- Experienced Leadership: Dr. Guofeng Cheng and the AusperBio team bring expertise in drug development and commercialization.
- Strategic Market Positioning: Targeting China for the Phase III program leverages a massive patient population and a favorable regulatory environment (breakthrough designation).
The biotech venture capital market continues to be robust for companies with innovative platforms addressing high-impact diseases, especially those with late-stage assets. AusperBio’s ability to attract such substantial funding in a competitive environment underscores its strong value proposition and the belief among investors that it is well-positioned to achieve its ambitious goals.
Official Responses: Leadership’s Vision and Investor Alignment
The official statements and implied perspectives surrounding AusperBio’s Series C funding round paint a clear picture of a company and its investors aligned on a transformative vision for chronic hepatitis B treatment.
Dr. Guofeng Cheng’s Vision: An Inflection Point Towards a Functional Cure
Dr. Guofeng Cheng, co-founder and CEO of AusperBio, articulated the profound significance of this financing, framing it as "an important inflection point for AusperBio." This phrase is carefully chosen, signifying a critical juncture where the company transitions from primarily a research and development entity to one poised for commercialization and advanced clinical execution. The funding is not merely about sustaining operations but about accelerating tangible progress toward patient impact.
His emphasis on advancing AHB-137 "toward potential commercialisation" highlights the immediate, near-term objective. This involves not only completing the rigorous Phase III registrational program but also establishing the necessary infrastructure for manufacturing, distribution, and market access. For a biotech company, moving from clinical development to commercial readiness is a complex and capital-intensive undertaking, and this funding round provides the critical resources for that transition.
Simultaneously, Dr. Cheng’s commitment to "developing next-generation therapies for CHB" demonstrates a long-term strategic vision. AusperBio is not content with a single successful drug but aims to build a comprehensive pipeline that can address the multifaceted challenges of CHB. This includes AHB-171 and, more broadly, "next-generation combination treatment approaches." This forward-looking perspective positions AusperBio as a leader in innovation, continually striving for more effective and ultimately curative solutions.
The CEO’s gratitude for "the continued confidence of our existing investors" speaks to the sustained belief in AusperBio’s capabilities and progress. The consistent support from firms like HanKang Capital, Qiming Venture Partners, and CDH Investments validates the company’s scientific integrity and operational efficiency over time. The welcome extended to "RA Capital to AusperBio" signifies the addition of a new, highly respected voice in the healthcare investment community, bringing fresh perspectives and potentially new strategic insights.
Ultimately, Dr. Cheng’s statement culminates in the overarching strategic goal: "to advance our strategy toward functional cure and unlock new opportunities across our oligonucleotide platforms." This reasserts the company’s commitment to transforming CHB treatment from lifelong management to a curative outcome. It also hints at the broader applicability of AusperBio’s oligonucleotide and delivery platform technologies beyond CHB, suggesting future pipeline expansion into other diseases, leveraging their core scientific strengths. His leadership portrays a blend of immediate commercial focus and ambitious long-term innovation.
Statements from Investors: Validation of Strategy and Market Potential
While specific direct quotes from the participating investors beyond RA Capital’s involvement were not provided, their collective participation and the scale of the investment convey a strong message of validation.
The decision of an "undisclosed strategic investor" to lead the round is particularly noteworthy. Strategic investors often bring more than just capital; they may offer invaluable industry expertise, market access channels, potential partnership opportunities, or even future acquisition prospects. Their leadership suggests a deep understanding of the CHB market, AusperBio’s technology, and its competitive advantage, indicating a belief in its ability to significantly disrupt the existing treatment landscape.
RA Capital Management’s participation, as a new investor, is a strong endorsement. RA Capital is known for its rigorous due diligence and expertise in identifying high-potential companies in the life sciences sector. Their investment signals that AusperBio’s scientific platform, clinical data, and commercial strategy have met their stringent criteria for innovation, market opportunity, and execution capability. Their involvement often attracts further investor interest and adds credibility to a company’s profile.
The continued investment from existing backers like HanKang Capital, Qiming Venture Partners, and CDH Investments underscores their satisfaction with AusperBio’s progress and their belief in its future trajectory. For venture capital firms, follow-on investments in later rounds are a clear indication that previous milestones have been met or exceeded, and that the company remains a compelling growth story. This sustained support demonstrates a long-term commitment to AusperBio’s mission and confidence in its management team’s ability to deliver on its promises.
Collectively, the investor responses, both explicit and implicit, suggest a consensus that AusperBio is addressing a critical unmet medical need with a differentiated and promising scientific approach. They are betting on the company’s ability to navigate late-stage clinical development, secure regulatory approvals, and ultimately bring a transformative therapy to market, potentially redefining the standard of care for chronic hepatitis B.
Implications: Reshaping CHB Treatment and AusperBio’s Future
The successful $120 million Series C funding round for AusperBio carries profound implications, not only for the company itself but also for the millions of people living with chronic hepatitis B and the broader biopharmaceutical industry. This investment marks a significant step towards a future where CHB may no longer be a lifelong burden but a curable disease.
Impact on Chronic Hepatitis B Treatment
The primary implication of this funding is the accelerated potential for AHB-137 to redefine CHB management. With substantial capital dedicated to its Phase III registrational program and commercial readiness, AHB-137 is poised to become one of the leading candidates for a functional cure. If successful, its ability to suppress HBsAg, inhibit viral DNA, and reactivate the immune system could offer patients a finite treatment course with sustained viral control, liberating them from the daily regimen of current therapies. This would represent a paradigm shift, significantly improving patient quality of life, reducing long-term health complications like cirrhosis and liver cancer, and alleviating the immense psychological burden associated with chronic illness.
Furthermore, the funding for AHB-171 and next-generation combination therapies suggests a future where CHB treatment could involve synergistic approaches, potentially combining different oligonucleotide modalities or even novel agents to achieve higher functional cure rates. This multi-pronged attack could overcome the limitations of monotherapies and tailor treatments to individual patient profiles, moving towards personalized medicine for CHB.
AusperBio’s Future Trajectory
For AusperBio, this funding round is transformative. It solidifies the company’s financial foundation, enabling it to execute its ambitious clinical and commercial strategies without immediate capital constraints. The capital will fuel expansion in R&D, potentially allowing for the exploration of new targets and the diversification of its pipeline beyond CHB, leveraging its core oligonucleotide and delivery platform technologies. This could include other liver diseases or conditions where targeted gene modulation offers therapeutic potential.
The investment also enhances AusperBio’s market positioning. Being well-funded with late-stage assets and a robust early-stage pipeline makes the company an attractive partner for larger pharmaceutical companies looking to expand their infectious disease portfolios. It could also pave the way for future liquidity events, such as an initial public offering (IPO), allowing public investors to participate in AusperBio’s growth story. The validation from strategic and specialist investors also boosts the company’s credibility within the scientific and financial communities.
Broader Biotech and Oligonucleotide Market Implications
AusperBio’s success could serve as a powerful validation for the entire oligonucleotide therapeutic class, particularly for the treatment of widespread infectious diseases. As more oligonucleotide drugs reach late-stage development and commercialization for large patient populations, it will strengthen confidence in this modality’s ability to tackle complex diseases beyond rare genetic disorders. This could encourage further investment and research into ASO and siRNA technologies across the biopharmaceutical industry.
Moreover, the focus on a "functional cure" for CHB sets a new benchmark for therapeutic ambition. It pushes the boundaries of what is considered achievable in chronic infectious disease management, potentially inspiring similar curative quests for other persistent viral infections. The advanced delivery technology embodied by Au-HALO also highlights the critical importance of sophisticated drug delivery systems in realizing the full potential of nucleic acid-based medicines.
Challenges and Opportunities Ahead
Despite the significant momentum, AusperBio faces considerable challenges. The Phase III trial for AHB-137, while underway, is a complex and costly endeavor. Demonstrating statistically significant efficacy and a favorable safety profile in a large patient population is paramount for regulatory approval. Navigating the regulatory landscapes in different regions, particularly for a novel drug class, will require meticulous planning and execution.
Commercialization itself presents its own set of hurdles, including manufacturing at scale, establishing effective sales and marketing channels, and securing market access and favorable pricing, especially in diverse global healthcare systems. Competition in the CHB space, with other companies also pursuing curative therapies, will remain fierce.
However, these challenges are matched by immense opportunities. The potential to offer a functional cure for CHB could alleviate a massive global health burden, transforming the lives of hundreds of millions. AusperBio’s commitment to innovation, backed by substantial financial resources and a strong investor base, positions it uniquely to lead this charge, ushering in a new era for chronic hepatitis B treatment and further solidifying the role of oligonucleotide therapeutics in modern medicine.
